当前位置: 首页 > 详情页

Predictive tool for intravenous immunoglobulin resistance of Kawasaki disease in Beijing

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Department of Cardiovascular Diseases, Children’s Hospital Capital Institute of Pediatrics, Beijing, China [2]Department of Rheumatology and Immunology, Beijing Children’s Hospital, Capital Medical University, Beijing, China
出处:
ISSN:

关键词: cardiology statistics

摘要:
Objective To construct a predictive tool for the efficacy of intravenous immunoglobulin (IVIG) therapy in children with Kawasaki disease (KD) in Beijing, China. Design This was a cohort study. Data set (including clinical profiles and laboratory findings) of children with KD diagnosed between 1 January 2010 and 31 December 2015 was used to analyse the risk factors and construct a scoring system. Data set of children with KD diagnosed between 1 January 2016 and 1 December 2016 was used to validate this model. Setting Children's Hospital Capital Institute of Pediatrics and Beijing Children's Hospital. Patients 2102 children diagnosed with KD. Interventions No. Main outcome measures Responsiveness to IVIG. Results The predictive tool included C reactive protein >= 90 mg/L (3 points), neutrophil percentage >= 70% (2.5 points), sodium ion concentration < 135 mmol/L (3 points), albumin < 35 g/L (2.5 points) and total bilirubin > 20 mu mol/L (5 points), which generated an area under the the receiver operating characteristic curve of 0.77 (95% CI 0.71 to 0.82) for the internal validation data set, and 0.69 (95% CI 0.58 to 0.81) and 0.63 (95% CI 0.53 to 0.72) for two external validation data sets, respectively. If a total of >= 6 points were considered high-risk for IVIG resistance, sensitivity and specificity were 56% and 79% in the internal verification, and the predictive ability was similar in the external validation. Conclusions The predictive tool is helpful in early screening of high-risk IVIG resistance of KD in the Beijing area. Consequently, it will guide the clinician in selecting appropriate individualised regimens for the initial treatment of this disease, which is important for the prevention of coronary complications.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 3 区 医学
小类 | 2 区 儿科
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 儿科
JCR分区:
出版当年[2017]版:
Q1 PEDIATRICS
最新[2023]版:
Q1 PEDIATRICS

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Department of Cardiovascular Diseases, Children’s Hospital Capital Institute of Pediatrics, Beijing, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Cardiovascular Diseases, Children’s Hospital Capital Institute of Pediatrics, Beijing, China [2]Department of Rheumatology and Immunology, Beijing Children’s Hospital, Capital Medical University, Beijing, China [*1]Department of Cardiovascular Diseases, Children’s Hospital Capital Institute of Pediatrics, Beijing 100020, China [*2]Department of Rheumatology and Immunology, Beijing Children’s Hospital, Capital Medical University, Beijing 100020, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:17044 今日访问量:0 总访问量:913 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院